Increased Risk of Developing Atrophic Gastritis in Patients Infected with CagA⁺Helicobacter pylori

References

• Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995;19 Suppl 1:37–43.
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Klinkenberg-Knol EC, Vandenbroucke-Grauls CMJE, Appelmelk BJ, Schenk BE, Meuwissen SCM. Role of Helicobacter pylori in the pathogenesis of atrophic gastritis. Scand J Gastroenterol 1997;32 Suppl 223:28–34.
   PubMed Web of Science ®Google Scholar
• Varis K. Surveillance of pernicious anemia. In: Sherlock P, Morson BC, Barbara L, Veronesi U, editors. Precancerous lesions of the gastrointestinal tract. New York: Raven Press; 1983. p. 189–94.
   Google Scholar
• Sipponen P, Kekki M, Haapakoski J, Ihamaki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985;35: 173–7.
   Google Scholar
• Correa P. A human model of gastric carcinogenesis. Cancer Res 1988;48:3554–60.
   PubMed Web of Science ®Google Scholar
• Perez-Perez GI, Bhat N, Gaensbauer J, Fraser A, Taylor DN, Kuipers EJ, et al. Country-specific constancy by age in cagA+ proportion of Helicobater pylori infections. Int J Cancer 1997; 72:453–6.
   Google Scholar
• Atherton JC, Cao P, Peek RM Jr, Tummuru MK, Blaser MJ. Cover TL. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori: association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995; 270:17771–7.
   Google Scholar
• Cover TL. The vacuolating cytotoxin of Helicobacter pylori. Mol Microbiol 1996;20:241–6.
   PubMed Web of Science ®Google Scholar
• Crabtree JE, Taylor JD, Wyatt JI, Heatley RV, Shallcross RM, Tompkins DS, et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration and gastric pathology. Lancet 1991;338:332–5.
   PubMed Web of Science ®Google Scholar
• Weel JFL, van der Hulst RWM, Gerrits Y, Rooda P, Feller M, Dankert J, et al. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis 1996;173:1171–5.
   PubMed Web of Science ®Google Scholar
• Crabtree JE, Farmery SM, Lindley IJD, Figura N, Peichl P, Tompkins DS. CagA/Cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines. J Clin Pathol 1994;47:945–50.
   PubMed Web of Science ®Google Scholar
• Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995; 55:2111–5.
   PubMed Web of Science ®Google Scholar
• Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997;40:297–301.
   PubMed Web of Science ®Google Scholar
• Maeda S, Ogura K, Yoshida H, Karai F, Ikenoue T, Kato N, et al. Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan. Gut 1998; 42:338–43.
   PubMed Web of Science ®Google Scholar
• Shimoyama T, Fukuda S, Tanaka M, Mikami T, Saito Y, Murakata A. High prevalence of the cagA-positive Helicobacter pylori strains in Japanese asymptomatic patients and gastric cancer patients. Gastroenterology 1997;32:465–8.
   Google Scholar
• Westerweld BD, Pals G, Lamers CBHW, Defize J, Pronk JC, Frants RR, et al. Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer 1987;59:952–8.
   PubMedGoogle Scholar
• Miki K, Ichinose M, Ishikawa KB, Yahagi N, Matsushima M, Kakei N, et al. Clinical application of serum pepsinogen I and pepsinogen II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993;84:1086–90.
   PubMedGoogle Scholar
• Yoshihara M, Sumii K, Haruma K, Kiyohara K, Hattori N, Tanaka S, et al. The usefulness of gastric mass screening using serum pepsinogen levels compared with photofluorography. Hiroshima J Med Sci 1997;46:81–6.
   PubMedGoogle Scholar
• Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, Kitadai Y, et al. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol 1998;93:1090–6.
   PubMed Web of Science ®Google Scholar
• Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999;44:693–7.
   PubMed Web of Science ®Google Scholar
• Nomura AMY, Stemmermann GN, Samloff IM. Serum pepsinogen I as a predictor of stomach cancer. Ann Int Med 1980;93:537–40.
   PubMedGoogle Scholar
• Kodoi A, Yoshihara M, Sumii K, Haruma K, Kajiyama G. Serum pepsinogen in screening for gastric cancer. J Gastroenterol 1995;30:452–60.
   Google Scholar
• Varis K, Samloff IM, Ihamäki T, Siurala M. An appraisal of tests for severe atrophic gastritis in relatives of patients with pernicious anemia. Dig Dis Sci 1979;24:187–91.
   Google Scholar
• Varis K, Kekki M, Härkönen M, Sipponen P, Samloff IM. Serum pepsinogen I and serum gastrin in screening of atrophic pangastritis with high risk of gastric cancer. Scand J Gastroenterol 1991;186:117–23.
   Google Scholar
• Kekki M, Samloff IM, Vans K, Ihamäki T. Serum pepsinogen I and serum gastrin in the screening of severe atrophic corpus gastritis. Scand J Gastroenterol 1991;26:109–16.
   Google Scholar
• Knight T, Wyatt J, Wilson A, Greaves S, Newell D, Hengels K, et al. Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in high risk groups. Br J Cancer 1996;73:819–24.
   PubMed Web of Science ®Google Scholar
• Lindgren A, Burman P, Kilander AF, Nilsson O, Lindstedt G. Serum antibodies to H+, K+-ATPase, serum pepsinogen A and Helicobacter pylori in relation to gastric mucosa morphology in patients with low or low-normal concentrations of serum cobalamins. Eur J Gastroenterol Hepatol 1998;10: 583–8.
   Google Scholar
• Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, et al. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Scand J Gastroenterol 2000;35:950–6.
   PubMed Web of Science ®Google Scholar
• Lindgren A, Lindstedt G, Kilander AF. Advantages of serum pepsinogen A combined with gastrin or pepsinogen C as first-line analytes in the evaluation of suspected cobalamin deficiency: a study in patients previously not subjected to gastrointestinal surgery. J Intern Med 1998;244:341–9.
   Google Scholar
• Samloff IM. Pepsinogens I and II. Purification from gastric mucosa and radioimmunoassay in serum. Gastroenterology 1981;82:26–33.
   Google Scholar
• Lelwala-Guruge J, Nilsson I, Ljungh Å, Wadstrom T. Cell surface proteins of Helicobacter pylori as antigens in an ELISA and a comparison with three commercial ELISA. Scand J Infect Dis 1992:24;457–65.
   Google Scholar
• Nilsson I, Ljungh Å, Aleljung P, Wadstrom T. Immunoblot assay for serodiagnosis of Helicobacter pylori infections. J Clin Microbiol 1997;35: 427–32.
   Google Scholar
• Webb PM, Crabtree JE, Forman D, the Eurogast Study Group. Gastric cancer, cytotoxin-associated gene A-positive Helicobacter pylori and serum pepsinogens: an international study. Gastroenterology 1999;116: 269–76.
   Google Scholar
• Kuipers EJ, Perez-Perez GI, Meuwissen SG, Blaser MJ. Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst 1995;87:1777–80.
   PubMed Web of Science ®Google Scholar